Do analysts prefer IBAC or QTRX?

Quanterix has a consensus target price of $3.50, indicating a potential upside of 35.14%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable valuation and earnings, IBAC or QTRX?

IB Acquisition has higher earnings, but lower revenue than Quanterix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Quanterix $138.90M 0.88 -$107.15M -$2.63 N/A

Does the media refer more to IBAC or QTRX?

In the previous week, Quanterix had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Quanterix and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Quanterix's score of -0.44 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Quanterix 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer IBAC or QSI?

Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 35.17%. Given Quantum-Si's higher possible upside, analysts clearly believe Quantum-Si is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, IBAC or QSI?

IB Acquisition has higher earnings, but lower revenue than Quantum-Si. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Quantum-Si $2.44M 66.02 -$101.34M -$0.46 N/A

Does the media favor IBAC or QSI?

In the previous week, Quantum-Si had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Quantum-Si and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Quantum-Si's score of 0.42 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CDXS or IBAC?

Codexis presently has a consensus target price of $5.00, indicating a potential upside of 220.51%. Given Codexis' higher probable upside, analysts clearly believe Codexis is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IB Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, CDXS or IBAC?

IB Acquisition has lower revenue, but higher earnings than Codexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.43 -$43.97M -$0.34 N/A IB Acquisition N/A N/A N/A N/A N/A

Is CDXS or IBAC more profitable?

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% IB Acquisition N/A N/A N/A

Does the media favor CDXS or IBAC?

In the previous week, Codexis had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Codexis and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Codexis' score of 0.27 indicating that IB Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral IB Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend IBAC or MXCT?

MaxCyte has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 MaxCyte 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, IBAC or MXCT?

IB Acquisition has higher earnings, but lower revenue than MaxCyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A MaxCyte $33.03M 4.28 -$44.63M -$0.33 N/A

Does the media prefer IBAC or MXCT?

In the previous week, MaxCyte had 6 more articles in the media than IB Acquisition. MarketBeat recorded 9 mentions for MaxCyte and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat MaxCyte's score of 0.43 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate IBAC or SEER?

Seer has a consensus target price of $4.00, indicating a potential upside of 92.31%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Seer 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, IBAC or SEER?

IB Acquisition has higher earnings, but lower revenue than Seer. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Seer $16.58M 6.90 -$73.60M -$1.22 N/A

Is IBAC or SEER more profitable?

IB Acquisition has a net margin of 0.00% compared to Seer's net margin of -478.05%. IB Acquisition's return on equity of 0.00% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets IB Acquisition N/A N/A N/A Seer -478.05% -27.23% -23.99%

Does the media prefer IBAC or SEER?

In the previous week, Seer had 6 more articles in the media than IB Acquisition. MarketBeat recorded 9 mentions for Seer and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Seer's score of -0.29 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Seer 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

IB Acquisition (IBAC) Competitors

$10.87 +0.07 (+0.61%)

Closing price 08/14/2026 03:50 PM Eastern

Extended Trading

$10.86 0.00 (-0.01%)

As of 08/14/2026 07:34 PM Eastern

Compare

IBAC vs. QTRX, QSI, CDXS, MXCT, and SEER

Should you buy IB Acquisition stock or one of its competitors? IB Acquisition's main competitors and comparable companies include Quanterix (QTRX), Quantum-Si (QSI), Codexis (CDXS), MaxCyte (MXCT), and Seer (SEER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IB Acquisition compare to Quanterix?

IB Acquisition (NASDAQ:IBAC) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Quanterix has a consensus target price of $3.50, indicating a potential upside of 35.14%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

IB Acquisition has a net margin of 0.00% compared to Quanterix's net margin of -80.25%. IB Acquisition's return on equity of 0.00% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Quanterix	-80.25%	-26.09%	-19.03%

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IB Acquisition has higher earnings, but lower revenue than Quanterix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Quanterix	$138.90M	0.88	-$107.15M	-$2.63	N/A

In the previous week, Quanterix had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Quanterix and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Quanterix's score of -0.44 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Quanterix	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

IB Acquisition and Quanterix tied by winning 5 of the 10 factors compared between the two stocks.

How does IB Acquisition compare to Quantum-Si?

IB Acquisition (NASDAQ:IBAC) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

IB Acquisition has higher earnings, but lower revenue than Quantum-Si.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Quantum-Si	$2.44M	66.02	-$101.34M	-$0.46	N/A

IB Acquisition has a net margin of 0.00% compared to Quantum-Si's net margin of -6,138.26%. IB Acquisition's return on equity of 0.00% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Quantum-Si	-6,138.26%	-45.05%	-41.10%

39.9% of Quantum-Si shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 35.17%. Given Quantum-Si's higher possible upside, analysts clearly believe Quantum-Si is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quantum-Si had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Quantum-Si and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Quantum-Si's score of 0.42 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Quantum-Si beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

How does IB Acquisition compare to Codexis?

Codexis (NASDAQ:CDXS) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Codexis presently has a consensus target price of $5.00, indicating a potential upside of 220.51%. Given Codexis' higher probable upside, analysts clearly believe Codexis is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IB Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
IB Acquisition	N/A	N/A	N/A

78.5% of Codexis shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Codexis had 8 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Codexis and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Codexis' score of 0.27 indicating that IB Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
IB Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

IB Acquisition has lower revenue, but higher earnings than Codexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.43	-$43.97M	-$0.34	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Codexis beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

How does IB Acquisition compare to MaxCyte?

IB Acquisition (NASDAQ:IBAC) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, MaxCyte had 6 more articles in the media than IB Acquisition. MarketBeat recorded 9 mentions for MaxCyte and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat MaxCyte's score of 0.43 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

MaxCyte has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IB Acquisition has higher earnings, but lower revenue than MaxCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
MaxCyte	$33.03M	4.28	-$44.63M	-$0.33	N/A

IB Acquisition has a net margin of 0.00% compared to MaxCyte's net margin of -114.77%. IB Acquisition's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
MaxCyte	-114.77%	-18.52%	-15.77%

Summary

MaxCyte beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

How does IB Acquisition compare to Seer?

IB Acquisition (NASDAQ:IBAC) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Seer had 6 more articles in the media than IB Acquisition. MarketBeat recorded 9 mentions for Seer and 3 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.60 beat Seer's score of -0.29 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Seer	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

IB Acquisition has higher earnings, but lower revenue than Seer.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Seer	$16.58M	6.90	-$73.60M	-$1.22	N/A

75.2% of Seer shares are owned by institutional investors. 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Seer has a consensus target price of $4.00, indicating a potential upside of 92.31%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

IB Acquisition has a net margin of 0.00% compared to Seer's net margin of -478.05%. IB Acquisition's return on equity of 0.00% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Seer	-478.05%	-27.23%	-23.99%

Summary

Seer beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

Get IB Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBAC vs. The Competition

Export

Metric	IB Acquisition	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.54M	$9.56B	$7.03B	$13.07B
Dividend Yield	N/A	1.46%	2.57%	10.64%
P/E Ratio	N/A	60.31	271.26	25.40
Price / Sales	N/A	105.46	622.95	105.59
Price / Cash	N/A	26.11	75.70	53.27
Price / Book	N/A	37.50	12.92	6.21
Net Income	N/A	$56.66B	$3.45B	$347.71M
7 Day Performance	0.43%	0.29%	1.16%	1.08%
1 Month Performance	0.84%	2.08%	2.17%	1.87%
1 Year Performance	3.34%	17.23%	62.38%	20.79%

IB Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBAC IB Acquisition	N/A	$10.87 +0.6%	N/A	+3.3%	$54.54M	N/A	N/A	N/A	Positive News Short Interest Decrease High Trading Volume
QTRX Quanterix	1.6001 of 5 stars	$4.03 +5.2%	$4.00 -0.7%	-43.3%	$189.85M	$138.90M	N/A	460	News Coverage Earnings Report Analyst Forecast
QSI Quantum-Si	2.6584 of 5 stars	$0.81 +7.9%	$1.00 +22.8%	-32.7%	$177.34M	$2.44M	N/A	150	News Coverage Earnings Report Analyst Downgrade Options Volume Gap Down
CDXS Codexis	2.9749 of 5 stars	$1.47 -0.7%	$5.00 +240.1%	-48.2%	$133.62M	$70.39M	N/A	250	News Coverage Earnings Report Analyst Downgrade
MXCT MaxCyte	3.3897 of 5 stars	$1.18 +6.3%	$5.00 +323.7%	-2.9%	$126.40M	$33.03M	N/A	80	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBAC) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IB Acquisition (IBAC) Competitors

IBAC vs. QTRX, QSI, CDXS, MXCT, and SEER

How does IB Acquisition compare to Quanterix?

Summary

How does IB Acquisition compare to Quantum-Si?

Summary

How does IB Acquisition compare to Codexis?

Summary

How does IB Acquisition compare to MaxCyte?

Summary

How does IB Acquisition compare to Seer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IB Acquisition (IBAC) Competitors

IBAC vs. QTRX, QSI, CDXS, MXCT, and SEER

How does IB Acquisition compare to Quanterix?

Do analysts prefer IBAC or QTRX?

Is IBAC or QTRX more profitable?

Do insiders & institutionals hold more shares of IBAC or QTRX?

Which has preferable valuation and earnings, IBAC or QTRX?

Does the media refer more to IBAC or QTRX?

Summary

How does IB Acquisition compare to Quantum-Si?

Which has stronger earnings & valuation, IBAC or QSI?

Is IBAC or QSI more profitable?

Do insiders and institutionals hold more shares of IBAC or QSI?

Do analysts prefer IBAC or QSI?

Does the media favor IBAC or QSI?

Summary

How does IB Acquisition compare to Codexis?

Do analysts recommend CDXS or IBAC?

Is CDXS or IBAC more profitable?

Do insiders & institutionals hold more shares of CDXS or IBAC?

Does the media favor CDXS or IBAC?

Which has stronger earnings and valuation, CDXS or IBAC?

Summary

How does IB Acquisition compare to MaxCyte?

Do institutionals and insiders hold more shares of IBAC or MXCT?

Does the media prefer IBAC or MXCT?

Do analysts recommend IBAC or MXCT?

Which has better earnings & valuation, IBAC or MXCT?

Is IBAC or MXCT more profitable?

Summary

How does IB Acquisition compare to Seer?

Does the media prefer IBAC or SEER?

Which has preferable valuation and earnings, IBAC or SEER?

Do insiders and institutionals believe in IBAC or SEER?

Do analysts rate IBAC or SEER?

Is IBAC or SEER more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools